Gonadotropin releasing hormone agonist triggering for in vitro maturation cycles

Anat Hershko Klement*, Daniella Navve, Yehudith Ghetler, Amir Wiser, Tal Shavit, Omer Weitzner, Adrian Shulman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The objective was to evaluate the outcomes of in vitro maturation (IVM) cycles using gonadotropin releasing hormone agonist (GnRH-ag) triggering. A retrospective cohort of IVM cycles from January 2015 to December 2019 in a single university-affiliated centre was examined. Main outcome measures were: (i) IVM maturation rate; and (ii) IVM maturation result. Secondary outcome measures were: (i) metaphase II (MII) rate on the day of egg retrieval; (ii) final MII maturation rate; and (iii) pregnancy rates. A total of 98 IVM cycles were performed during the study period: 50 (51%) were triggered with GnRH-ag (17 received FSH priming and 33 did not) and 48 cycles (49%) were triggered by hCG (37 with FSH priming and 11 without). A significant (p = 0.01) difference was noticed in maturation rate on egg retrieval day, in favour of the GnRH-ag group, although not in the final maturation rate achieved. Pregnancy rates were comparable between treatment sub-groups. GnRH-ag triggering in IVM cycles is an optional triggering mode and can be considered an acceptable option, especially when fertility preservation is a concern. GnRH agonists resulted in higher maturation rate on day of oocyte retrieval, but no difference in the total maturation rate.

Original languageEnglish
Pages (from-to)516-521
Number of pages6
JournalHuman Fertility
Issue number3
StatePublished - 16 Dec 2020


  • In vitro oocyte maturation techniques
  • gonadotropin-releasing hormone
  • in vitro fertilisation
  • ovulation


Dive into the research topics of 'Gonadotropin releasing hormone agonist triggering for in vitro maturation cycles'. Together they form a unique fingerprint.

Cite this